MARKET

ONCY

ONCY

Oncolytics Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.240
+0.070
+2.21%
Pre Market: 3.110 -0.13 -4.01% 07:12 03/04 EST
OPEN
3.200
PREV CLOSE
3.170
HIGH
3.290
LOW
3.060
VOLUME
261
TURNOVER
--
52 WEEK HIGH
4.700
52 WEEK LOW
0.9400
MARKET CAP
140.29M
P/E (TTM)
-4.1586
1D
5D
1M
3M
1Y
5Y
Enforcement Notice - Hearing - IIROC Holds Disciplinary Hearing for St. Albert Investment Advisor Gordon Albert Malic
ALBERT, AB, March 2, 2021 /CNW/ - A hearing has been scheduled before a Hearing Panel of the Investment Industry Regulatory Organization of Canada (IIROC) in the matter of Gordon Albert Malic. The hearing concerns allegations that Mr.
CNW Group · 1d ago
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights
and , /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on , at to discuss a corporate update and financial results for the fourth quarter and full year 2020.
PR Newswire - PRF · 6d ago
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies
, /PRNewswire/ --   -  The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent headline-grabbing announcements pertaining to COVID-19. A series of discoveries and breakthroughs in oncology, especially those tar...
PR Newswire - PRF · 02/24 16:00
Thinking about buying stock in Vascular Biogenics, Oncolytics Biotech, Protalix Biotherapeutics, AMC Entertainment, or Applied DNA Sciences?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VBLT, ONCY, PLX, AMC, and APDN.
PR Newswire - PRF · 02/23 13:30
Extensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of Cancer
PALM BEACH,  Fla., /PRNewswire/ -- In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to come. T-cell therap...
PR Newswire - PRF · 02/23 13:30
VET, TCOM, TTM and ZI among premarket gainers
Yunhong CTI (CTIB) +77%.Dawson Geophysical (DWSN) +39%.ReTo Eco-Solutions (RETO) +31%.Vascular Biogenics (VBLT) +29%.Vinco Ventures (BBIG) +35%.Sunesis Pharmaceuticals (SNSS) +12%.Oncolytics Biotech (ONCY) +11% on encouraging pelareorep + CAR T data in sol...
Seekingalpha · 02/23 13:18
Oncolytics surges on encouraging pelareorep + CAR T data in solid tumors
Oncolytics Biotech (ONCY) has gained 13.6% in the premarket after announcing preclinical data from a study evaluating the treatment combination of pelareorep and chimeric antigen receptor (“CAR”) T cell in solid tumors.The data reported
Seekingalpha · 02/23 12:52
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22)
Benzinga · 02/23 12:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCY. Analyze the recent business situations of Oncolytics Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONCY stock price target is 8.41 with a high estimate of 14.85 and a low estimate of 4.747.
EPS
Institutional Holdings
Institutions: 57
Institutional Holdings: 1.51M
% Owned: 3.49%
Shares Outstanding: 43.30M
TypeInstitutionsShares
Increased
10
244.79K
New
11
40.73K
Decreased
4
3.49K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
Wayne Pisano
President/Chief Executive Officer/Director
Matthew Coffey
Chief Financial Officer/IR Contact Officer
Kirk Look
Corporate Executive
Andrew Guttadauro
Vice President
Allison Hagerman
Other
Rita Laeufle
Other
Michael Moore
Independent Director
Deborah Brown
Independent Director
Angela Holtham
Independent Director
Leonard Kruimer
Independent Director
William Rice
Independent Director
Bernd Seizinger
No Data
  • All
  • Financials
  • Insiders
More
About ONCY
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Webull offers kinds of Oncolytics Biotech, Inc. (USA) stock information, including NASDAQ:ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.